Emil Lou

6.8k total citations
194 papers, 3.0k citations indexed

About

Emil Lou is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Emil Lou has authored 194 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 47 papers in Cancer Research and 45 papers in Molecular Biology. Recurrent topics in Emil Lou's work include Cancer Genomics and Diagnostics (37 papers), Pancreatic and Hepatic Oncology Research (28 papers) and Colorectal Cancer Treatments and Studies (25 papers). Emil Lou is often cited by papers focused on Cancer Genomics and Diagnostics (37 papers), Pancreatic and Hepatic Oncology Research (28 papers) and Colorectal Cancer Treatments and Studies (25 papers). Emil Lou collaborates with scholars based in United States, Germany and Austria. Emil Lou's co-authors include Subbaya Subramanian, Clifford J. Steer, Sho Fujisawa, Rachel I. Vogel, Katia Manova‐Todorova, Venugopal Thayanithy, Malcolm A.S. Moore, Yevgeniy Romin, Sepideh Gholami and Afşar Barlas and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Emil Lou

171 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emil Lou United States 28 1.2k 888 449 447 438 194 3.0k
Tobias Pukrop Germany 35 1.7k 1.4× 1.0k 1.1× 564 1.3× 513 1.1× 200 0.5× 119 3.6k
Serge Romana France 29 1.6k 1.4× 968 1.1× 580 1.3× 334 0.7× 423 1.0× 108 4.4k
Robert A. Fenstermaker United States 35 1.3k 1.1× 718 0.8× 244 0.5× 587 1.3× 252 0.6× 132 3.5k
Judith Runnels United States 25 1.5k 1.3× 674 0.8× 637 1.4× 719 1.6× 564 1.3× 64 3.5k
Debra G. B. Leonard United States 36 2.0k 1.7× 1.2k 1.3× 540 1.2× 463 1.0× 182 0.4× 85 4.7k
Christopher A. Barker United States 34 936 0.8× 2.0k 2.3× 370 0.8× 308 0.7× 272 0.6× 131 4.0k
Matthew W. Wilson United States 34 1.0k 0.9× 1.3k 1.5× 271 0.6× 375 0.8× 111 0.3× 160 3.9k
Joanne Yu Canada 29 2.1k 1.8× 920 1.0× 1.0k 2.3× 272 0.6× 446 1.0× 45 4.1k
Gary D. Kao United States 41 2.7k 2.3× 1.3k 1.5× 888 2.0× 438 1.0× 545 1.2× 103 4.8k
Mary Jue Xu United States 11 1.1k 0.9× 569 0.6× 373 0.8× 150 0.3× 251 0.6× 42 2.2k

Countries citing papers authored by Emil Lou

Since Specialization
Citations

This map shows the geographic impact of Emil Lou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emil Lou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emil Lou more than expected).

Fields of papers citing papers by Emil Lou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emil Lou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emil Lou. The network helps show where Emil Lou may publish in the future.

Co-authorship network of co-authors of Emil Lou

This figure shows the co-authorship network connecting the top 25 collaborators of Emil Lou. A scholar is included among the top collaborators of Emil Lou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emil Lou. Emil Lou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Choucair, Khalil, Andrew Elliott, Matthew J. Oberley, et al.. (2025). Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma. PubMed. 4(1). e000551–e000551.
2.
Lou, Emil, et al.. (2025). Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response. JCO Clinical Cancer Informatics. 9(9). e2400160–e2400160. 1 indexed citations
3.
Lou, Emil, Marcel Grube, Axel Svedbom, et al.. (2024). Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer. JAMA Network Open. 7(2). e240407–e240407. 13 indexed citations
4.
Moustafa, Dina A., et al.. (2024). Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen. Vaccine. 42(26). 126476–126476. 3 indexed citations
5.
Lou, Emil, et al.. (2024). Tunneling Nanotubes: Implications for Chemoresistance. Results and problems in cell differentiation. 73. 353–373. 2 indexed citations
6.
Lou, Emil, et al.. (2024). Do tunneling nanotubes drive chemoresistance in solid tumors and other malignancies?. Biochemical Society Transactions. 52(4). 1757–1764. 1 indexed citations
7.
Baca, Yasmine, Joanne Xiu, Alex Farrell, et al.. (2024). Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy: PD-L1 and beyond.. Journal of Clinical Oncology. 42(16_suppl). 3518–3518. 1 indexed citations
8.
Millstein, Joshua, Joanne Xiu, Shivani Soni, et al.. (2024). Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data.. Journal of Clinical Oncology. 42(16_suppl). 3145–3145. 1 indexed citations
9.
Ascione, Liliana, et al.. (2024). Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book. 44(3). e431766–e431766. 24 indexed citations
10.
Faber, Erik B., Peter J. Hosein, Anthony F. Shields, et al.. (2024). Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets. JCO Precision Oncology. 8(8). e2300595–e2300595. 3 indexed citations
11.
Trabolsi, Asaad, Estelamari Rodríguez, Jennifer R. Ribeiro, et al.. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist. 29(11). e1480–e1491. 7 indexed citations
12.
13.
Florou, Vaia, Andrew Elliott, Matthew H. Bailey, et al.. (2023). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clinical Cancer Research. 29(17). 3408–3417. 10 indexed citations
14.
Shetty, Mihir, Andrew C. Nelson, Britt Erickson, et al.. (2022). GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors. Cancer Research Communications. 2(8). 784–794. 8 indexed citations
15.
Moser, Justin C., Ellaine Salvador, Kenneth D. Swanson, et al.. (2022). The Mechanisms of Action of Tumor Treating Fields. Cancer Research. 82(20). 3650–3658. 65 indexed citations
16.
Freeman‐Daily, Janet, Michael Fisch, Emil Lou, et al.. (2022). The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. JCO Oncology Practice. 18(8). 578–583. 23 indexed citations
17.
Vantanasiri, Kornpong, et al.. (2021). Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy — Oncolytics. 22. 1–12. 28 indexed citations
18.
Zhao, Xianda, et al.. (2018). Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. Translational research. 196. 62–70. 6 indexed citations
19.
Domingo‐Musibay, Evidio, Paari Murugan, Alessio Giubellino, et al.. (2018). Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. Journal for ImmunoTherapy of Cancer. 6(1). 58–58. 49 indexed citations
20.
Girard, Nicolas, Emil Lou, Christopher G. Azzoli, et al.. (2010). Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research. 16(2). 755–763. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tobias Pukrop Breakdown of academic impact, for papers by Serge Romana Breakdown of academic impact, for papers by Robert A. Fenstermaker Breakdown of academic impact, for papers by Judith Runnels Breakdown of academic impact, for papers by Debra G. B. Leonard Breakdown of academic impact, for papers by Christopher A. Barker Breakdown of academic impact, for papers by Matthew W. Wilson Breakdown of academic impact, for papers by Joanne Yu Breakdown of academic impact, for papers by Gary D. Kao Breakdown of academic impact, for papers by Mary Jue Xu
Rankless by CCL
2026